CRISIL monitoring report: no deviation in use of IPO proceeds in September 2026 quarter
CRISIL Ratings' monitoring agency report on the use of Amanta Healthcare's IPO money for the quarter ended September 30, 2026.
By ScoutQuest · · 2 min read
- Issue size
- Rs 12,600.00 lakhs
- Issue expenses
- Rs 2,284.81 lakhs (Rs 358.38 lakhs higher than estimated)
- Net proceeds revised
- from Rs 10,673.57 lakhs to Rs 10,315.19 lakhs
CRISIL Ratings Limited, the monitoring agency for Amanta Healthcare's Initial Public Offer, has issued its report on the utilisation of the issue proceeds for the quarter ended September 30, 2026.
What the report records
- Deviation from the objects of the issue: Not applicable.
- Range of Deviation: Not applicable.
In simple terms, a monitoring agency is an outside agency that tracks whether the money raised in a public issue is being used for the purposes stated in the offer document. For this quarter, the agency has recorded no deviation from those objects.
The money involved
- Issue size: Rs 12,600.00 lakhs, raised through a fresh issue of equity shares.
- Gross proceeds of the Fresh Issue: 12,600.00 (Rs in lakhs) — the amount CRISIL monitors.
- Less: Issue Expenses: 2,284.81 (Rs in lakhs).
- Net Proceeds: 10,315.19 (Rs in lakhs).
- Net proceeds were revised from Rs 10,673.57 lakhs to Rs 10,315.19 lakhs, because actual issue expenses were higher than estimated in the Prospectus by Rs 358.38 lakhs, and that amount was adjusted with general corporate purposes cost.
Issue background
- Issue period: Monday, September 01, 2025, to Wednesday, September 03, 2025.
- Type of issue: Initial Public Offer of equity shares.
- Sector: Pharmaceuticals.
- Promoters named in the report: Mr. Bhavesh Girishbhai Patel, Mrs. Jayshreeben Rohitkumar Patel, Mr. Vishal Ashokkumar Patel and Mr. Jitendrakumar Jashbhai Patel.
What this means for a retail investor
This is a periodic check on how IPO money is being spent. The main takeaway is that the monitoring agency records no deviation from the stated objects for the quarter. The one moving part is the cost of the issue itself: because actual issue expenses came in Rs 358.38 lakhs above the estimate, the net proceeds that reached the company were lower, at Rs 10,315.19 lakhs instead of Rs 10,673.57 lakhs, with the difference adjusted against general corporate purposes cost.
The report also carries a declaration by the agency that it does not perform an audit and undertakes no independent verification of the information or certifications it receives.
Also from Amanta Healthcare
Amanta Healthcare posts audio recording of November 4, 2026 post results conference call on website
4 Nov 2026
Amanta Healthcare Q2 FY27: revenue up 17.3% YoY, SteriPort Line 3 commissioned
4 Nov 2026
Amanta Healthcare commissions SteriPort Line 3, SteriPort capacity up 75% to 11.6 crore bottles
4 Nov 2026
More numbers
- Issue sizeRs 12,600.00 lakhs
- Gross proceeds of the Fresh Issue (Rs in lakhs)12,600.00
- Issue expenses (Rs in lakhs)2,284.81
- Net proceeds (Rs in lakhs)10,315.19
- Earlier net proceeds before revisionRs 10,673.57 lakhs
- Issue expenses higher than estimatedRs 358.38 lakhs
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.